Across TCGA pan-cancer cohorts, SEPTIN1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SEPTIN1 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SEPTIN1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SEPTIN1 expression acts as an unfavorable survival marker.
BRCA, HNSC, and UCEC are the cancer types where SEPTIN1 Mutation most reproducibly stratifies survival.